Manufacturer
NOVARTIS PHARMA STEIN AG
Contents
Imatinib mesilate
Indication
Hypereosinophilic syndrome, Acute lymphoblastic leukaemia, Acute lymphoid leukaemia relapse, Refractory acute lymphoid leukaemia, Myelodysplastic disease, Unresectable, metastatic malignant gastrointestinal stromal tumours, Mastocytosis, Chronic myeloid leukaemia, Dermatofibrosarcoma protuberans.
Instruction
Should be taken with food.
Drug interaction
Increased serum levels w/ CYP3A4 inhibitors (e.g. azole antifungals, macrolide antibiotics). Reduced serum levels w/ CYP3A4 inducers (e.g. carbamazepine, dexamethasone, phenobarbital, phenytoin, rifampicin). May increase serum levels of substrates of CYP3A4 (e.g. ciclosporin, pimozide, triazolo-benzodiazepines, dihydropyridine Ca channel blockers, certain statins), CYP2C9 (e.g. warfarin) and CYP2D6.
Malaysia
